Adverse event development in clinical oncology trials
Lancet Oncol
.
2016 Jul;17(7):e263.
doi: 10.1016/S1470-2045(16)30197-8.
Authors
Iris Walraven
1
,
Neil Aaronson
2
,
Jan-Jakob Sonke
1
,
Marcel Verheij
1
,
José Belderbos
3
Affiliations
1
Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam 1006 BE, Netherlands.
2
Department of Epidemiology and Biostatistics, Netherlands Cancer Institute, Amsterdam 1006 BE, Netherlands.
3
Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam 1006 BE, Netherlands. Electronic address:
[email protected]
.
PMID:
27396639
DOI:
10.1016/S1470-2045(16)30197-8
No abstract available
Publication types
Letter
Comment
MeSH terms
Clinical Trials as Topic
Humans
Medical Oncology*
Neoplasms*